HUE063275T2 - Gyógyszerészeti kombináció rákbetegség kezelésére - Google Patents

Gyógyszerészeti kombináció rákbetegség kezelésére

Info

Publication number
HUE063275T2
HUE063275T2 HUE18722621A HUE18722621A HUE063275T2 HU E063275 T2 HUE063275 T2 HU E063275T2 HU E18722621 A HUE18722621 A HU E18722621A HU E18722621 A HUE18722621 A HU E18722621A HU E063275 T2 HUE063275 T2 HU E063275T2
Authority
HU
Hungary
Prior art keywords
cancer
treatment
pharmaceutical combination
pharmaceutical
combination
Prior art date
Application number
HUE18722621A
Other languages
English (en)
Hungarian (hu)
Inventor
Garcia Carles Domenech
Alfon Coriat Jose Alberto
Montoyo Hector Perez
Segura Ginard Miguel Francisco
Lizcano De Vega Jose Miguel
Original Assignee
Ability Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ability Pharmaceuticals S A filed Critical Ability Pharmaceuticals S A
Publication of HUE063275T2 publication Critical patent/HUE063275T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE18722621A 2017-05-16 2018-05-15 Gyógyszerészeti kombináció rákbetegség kezelésére HUE063275T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382282 2017-05-16

Publications (1)

Publication Number Publication Date
HUE063275T2 true HUE063275T2 (hu) 2024-01-28

Family

ID=58765794

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18722621A HUE063275T2 (hu) 2017-05-16 2018-05-15 Gyógyszerészeti kombináció rákbetegség kezelésére

Country Status (15)

Country Link
US (3) US11260042B2 (enExample)
EP (2) EP4234035A3 (enExample)
JP (1) JP7208650B2 (enExample)
KR (1) KR102569052B1 (enExample)
CN (2) CN110636842A (enExample)
AU (1) AU2018269462B2 (enExample)
CA (1) CA3063625A1 (enExample)
CL (1) CL2019003288A1 (enExample)
ES (1) ES2955524T3 (enExample)
HU (1) HUE063275T2 (enExample)
IL (1) IL270676B2 (enExample)
MX (1) MX2019013683A (enExample)
PL (1) PL3624786T3 (enExample)
WO (1) WO2018210830A1 (enExample)
ZA (1) ZA201907286B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018269462B2 (en) 2017-05-16 2024-04-18 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
IL295067A (en) 2020-02-10 2022-09-01 Ability Pharmaceuticals S L Pharmaceutical combination for cancer treatment
CN120733048A (zh) * 2025-08-29 2025-10-03 天津医科大学总医院 一种用于治疗肺鳞癌的药物组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258816A (ja) * 1987-04-16 1988-10-26 Nippon Oil & Fats Co Ltd 抗癌剤組成物
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR101783817B1 (ko) 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
MY170185A (en) 2011-10-18 2019-07-09 Nestle Sa Composition for use in brain growth and/or cognitive and/or psychomotor development
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
AU2018269462B2 (en) * 2017-05-16 2024-04-18 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer

Also Published As

Publication number Publication date
EP3624786C0 (en) 2023-07-05
US20220257554A1 (en) 2022-08-18
US20240350449A1 (en) 2024-10-24
RU2019135507A (ru) 2021-06-16
US20210154166A1 (en) 2021-05-27
AU2018269462A1 (en) 2019-11-28
EP4234035A2 (en) 2023-08-30
JP7208650B2 (ja) 2023-01-19
WO2018210830A1 (en) 2018-11-22
EP4234035A3 (en) 2023-11-15
KR102569052B1 (ko) 2023-08-22
EP3624786B1 (en) 2023-07-05
BR112019023944A2 (pt) 2020-06-09
CA3063625A1 (en) 2018-11-22
US11260042B2 (en) 2022-03-01
MX2019013683A (es) 2020-01-15
PL3624786T3 (pl) 2023-10-30
IL270676B1 (en) 2024-07-01
JP2020520385A (ja) 2020-07-09
IL270676B2 (en) 2024-11-01
US12053449B2 (en) 2024-08-06
EP3624786A1 (en) 2020-03-25
RU2019135507A3 (enExample) 2021-09-03
KR20200005573A (ko) 2020-01-15
CN119950727A (zh) 2025-05-09
AU2018269462B2 (en) 2024-04-18
IL270676A (enExample) 2020-01-30
CN110636842A (zh) 2019-12-31
ZA201907286B (en) 2021-01-27
US12280033B2 (en) 2025-04-22
ES2955524T3 (es) 2023-12-04
CL2019003288A1 (es) 2020-05-08

Similar Documents

Publication Publication Date Title
ZA201806819B (en) Pharmaceutical combinations for the treatment of cancer
IL290149A (en) Combined treatment for cancer
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
PT3616720T (pt) Composição medicinal para tratamento de cancro
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL267795A (en) Combined treatment for cancer
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
IL256224B (en) Combined therapy for cancer treatment
IL258521A (en) Combination of treatments for cancer treatment
PT3576740T (pt) Tratamento de cancro
IL268463A (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
IL274626A (en) Cancer treatment
IL268416A (en) Pharmaceutical combinations for cancer treatment
IL266993A (en) Combined therapy for cancer treatment
IL261278A (en) Pharmaceutical compositions for the treatment of cancer
ZA201907286B (en) A pharmaceutical combination for the treatment of a cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL273835A (en) Combined product for cancer treatment
IL281782A (en) Drug combination for cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
IL253642A0 (en) Combined treatment for cancer
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer